Key Highlights
- Shares are trading at $7.44 in pre-market activity, up 420.08% from Wednesday's close of $1.43.
- Aethlon Medical entered a definitive all-stock Merger agreement with North Immunology, a privately held biotechnology company.
- A concurrent, oversubscribed private Placement is expected to provide approximately $180 million in gross proceeds, funding operations into the second half of 2028.
- Pre-merger Aethlon stockholders are expected to own approximately 4.75% of the combined company, which will trade under the new ticker NRTX.
Merger Agreement Triggers a Massive Pre-Market Move
Aethlon Medical (NASDAQ:AEMD) shares soared in pre-market trading Thursday after the company announced a definitive merger agreement for an all-stock transaction with North Immunology, a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases. Aethlon Medical is a San Diego-based clinical-stage medical device company that has been developing the Hemopurifier, an investigational extracorporeal device designed to remove harmful tumor-derived exosomes and enveloped viruses from the bloodstream.
Upon closing, the combined entity will operate as North Immunology, trading on the Nasdaq Capital Market under the new ticker symbol NRTX, with pre-merger Aethlon stockholders expected to own approximately 4.75% of the combined company and pre-merger North Immunology stockholders expected to own the remaining approximately 95.25%.
Oversubscribed Financing Funds the Combined Company Into 2028
The merger is paired with an oversubscribed private placement, supported by a syndicate of healthcare-focused institutional investors including Bain Capital Life Sciences and Janus Henderson Investors, expected to provide approximately $180 million in gross proceeds and fully fund the combined company's operations into the second half of 2028.
Deal Centers on a Late-Stage Atopic Dermatitis Candidate
The combined company's lead program, NOR-101, is a half-life extended bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation in atopic dermatitis. A Phase 1a study is expected to begin in the first quarter of 2027, with interim safety data expected by mid-2027 and Phase 1b and Phase 2b topline data expected in 2028. Aethlon stockholders will also receive contingent value rights tied to any future monetization of the company's legacy Hemopurifier business.
Outlook: Deal Closing Conditions Remain the Next Milestone
The transaction has been approved by both companies' boards and is expected to close in the first quarter of 2027, subject to stockholder approvals and other customary closing conditions. Progress toward those approvals, along with early clinical steps for NOR-101, will likely be the next catalysts shaping the stock.






Please wait processing your request...